Skip to main content

Advertisement

Table 2 Risk of cancer within 3 years of myositis onset with different MSAs compared to the general population

From: Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study

Autoantibodies Totala Observedb Expectedc SIR (95% CI)
Anti-TIF1-γ 89 34 1.97 17.28 (11.94, 24.14)
Anti-NXP2 42 3 0.37 8.14 (1.63, 23.86)
Anti-SAE1 13 4 0.31 12.92 (3.23, 32.94)
Anti-Mi-2 24 0 0.53 0 (0, 7.03)
Anti-HMGCR 21 1 0.33 3.0 (0.30, 16.83)
Anti-SRP 30 0 0.32 0 (0, 11.47)
Anti-MDA5 92 0 1.25 0 (0, 2.97)
Anti-Jo-1 63 3 1.01 2.98 (0.60, 8.74)
Anti-PL-7 33 0 0.71 0 (0, 5.24)
Anti-PL-12 17 2 0.34 5.92 (0.59, 21.31)
Anti-EJ 22 0 0.40 0 (0, 9.36)
Anti-OJ 1 0 0.06 0 (0, 58.78)
MSAs-d 170 11 2.76 3.99 (1.96, 7.14)
  1. Abbreviations: SIR standardized incidence ratio, MSAs myositis specific autoantibodies
  2. aNumber of autoantibody-positive patients
  3. bObserved cancer cases within 3 years of myositis onset
  4. cExpected cancer cases based on estimates in the general population in China, after adjustment for age and gender
  5. dPatients who were negative for all of the MSAs listed